Assay News and Research

RSS

Sequenom MassARRAY System detects EML4/ALK fusion gene in NSCLC

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today reported on a recently released publication in which the Sequenom MassARRAY System (for research use only) was used in a groundbreaking independent study that detected the transforming fusion gene EML4/ALK in non-small cell lung cancer.

30 May 2012

Lung in Oncology models for drug discovery launched by PRECOS

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has launched its Lung In ONcology model atlas (LION).

29 May 2012

Fluxion Biosciences announces launch of Discovery Services business

Fluxion Biosciences, a privately held drug discovery tools and services company, announced today that it is launching a Discovery Services business to support growing demand for assay support on Fluxion's unique cell analysis platforms.

From Fluxion Biosciences 29 May 2012

Single test developed that detects all known strains of H5N1

The close collaboration between scientists from the Experimental Therapeutics Centre (ETC) under the Agency for Science and Technology Research (A*STAR) and clinicians from Tan Tock Seng Hospital (TTSH) has enabled the successful development of the most comprehensive and rapid H5N1 bird flu test kit available to date.

29 May 2012

Scientists develop super-sensitive test that could detect diseases earlier

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

Ultra-sensitive test can diagnose diseases in their earliest stages

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.

25 May 2012

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

24 May 2012

Study confirms links between metabolic dysregulation, SDB and obesity

Weight loss improved both metabolic parameters and sleep-disordered breathing (SDB) in obese children in a new study from researchers in Belgium, confirming links between metabolic dysregulation, SDB and obesity.

24 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

Microfluidic chip can diagnose latent TB

Biomedical engineers at UC Davis have developed a microfluidic chip to test for latent tuberculosis. They hope the test will be cheaper, faster and more reliable than current testing for the disease.

23 May 2012

Noninvasive test can reduce feeding-related complications among premature infants

Tufts Medical Center researchers have shown that presence of a gene strongly linked to appetite regulation is highly predictive of a premature infant's readiness to feed orally. An analysis of just a drop of an infant's saliva could be the key to preventing many feeding problems and the expensive medical complications that can occur when infants are fed by mouth too early.

22 May 2012

Aushon plans global launch of new multiplex protein biomarker platform

Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance.

21 May 2012

BIOCRATES Life Sciences to introduce AbsoluteIDQ p180 and p150 research kits

Austrian BIOCRATES Life Sciences AG, prime developer of state-of-the-art metabolite biomarker panels, is about to launch new editions of two of its well-established research kit products -AbsoluteIDQ p180 and p150.

21 May 2012

ScreenCell, Affymetrix partner to distribute CTC platform

Affymetrix, Inc. and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

18 May 2012

NEC, SomaLogic release professional software tool

SomaLogic, Inc., and NEC Corporation today announced the release of SomaSuite, a professional software tool developed by NEC that provides simple, reliable and direct access to the highly multiplexed proteomic data generated by SomaLogic's SOMAscan proteomics assay technology.

18 May 2012

NanoString commences second clinical study of PAM50-based breast cancer assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay.

From NanoString Technologies 17 May 2012

Thermo Fisher signs asset purchase agreement with Nephromics for PlGF assay

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights to use PlGF for the diagnosis of pre-eclampsia or eclampsia. Clinical trials have shown that PlGF supports the diagnosis and risk prediction for preeclampsia.

From Thermo Fisher Scientific Inc. 16 May 2012

Lab21’s HCV drug resistance genotyping receives new patents in the U.S., Europe

Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.

15 May 2012